The study, published in Cancer Letters, identifies MDA-9/Syntenin—also known as syndecan-binding protein 1, or SDCBP—as a major regulator of aggressive HNSCC biology. MDA-9 is a scaffold protein, meaning that it helps organize molecular partners inside and outside cells rather than acting as a conventional enzyme. By bringing signaling proteins into the correct position, it can influence tumor-cell migration, invasion, angiogenesis and immune suppression. The VCU-led team found that MDA-9 is also important for maintaining cancer stem cells, a small but powerful population capable of renewing itself and generating new tumor cells.

The researchers tested IVMT-Rx-4, a small-molecule inhibitor designed to interfere with MDA-9/Syntenin’s interactions with partner proteins. In preclinical models of HNSCC, the compound sharply restricted tumor growth and metastasis, in some cases leaving treated animals tumor-free. The experiments did not reveal observable toxicity, an important result because a drug that attacks tumor-promoting machinery must still preserve the functions of healthy tissues. The findings indicate that MDA-9 may be unusually suitable for therapeutic targeting because laboratory models lacking the protein have shown no obvious physiological defects while displaying increased resistance to metastatic spread.

The compound’s most important effect appeared to involve the cancer stem-cell compartment. Unlike the bulk of a tumor, cancer stem cells can remain dormant, repair damage and recreate a diverse population of malignant cells after treatment. Their persistence is one reason cancers can return after apparently successful therapy. The VCU team used molecular and functional assays to show that MDA-9 supports stem-cell properties in HNSCC and that IVMT-Rx-4 can disrupt those properties. In effect, the drug targets the regenerative core of the tumor rather than merely reducing the visible mass of cancer cells.

One molecular indicator of this effect was BMI1, a transcriptional regulator associated with stemness and tumor-maintaining capacity in HNSCC. IVMT-Rx-4 suppressed BMI1 and reduced the ability of cancer cells to form new tumor populations. This result is significant because conventional chemotherapy may eliminate rapidly dividing cells while leaving behind resistant stem-like cells. The surviving population can then repopulate the tumor and acquire additional protective features. By interfering with MDA-9-dependent signaling, IVMT-Rx-4 appeared to prevent this rebound in experimental systems.

The study also reported evidence that the inhibitor can counter cisplatin resistance. When HNSCC cells were exposed to cisplatin, the proportion of stem-like, drug-tolerant cells increased. Treatment with IVMT-Rx-4 blocked that enrichment and, in some experiments, reversed characteristics associated with an already resistant state. Combining the experimental inhibitor with standard chemotherapy therefore produced a more pronounced anticancer effect than either approach alone. Although these results remain preclinical, they raise the possibility that MDA-9 inhibition could be used alongside existing therapy to prevent resistance from emerging or to restore sensitivity after it has developed.

MDA-9’s potential importance extends beyond HNSCC. Earlier work by Paul B. Fisher and colleagues first cloned the gene and established its role in cancer progression. The protein has since been linked to multiple stages of metastasis, including the ability of tumor cells to leave a primary lesion, survive in the bloodstream, attach to distant tissues and stimulate the formation of new blood vessels. MDA-9 also contributes to an immunologically “cold” tumor microenvironment, in which immune cells are less able to recognize or destroy malignant cells. These broad functions help explain why the protein is being investigated in prostate, breast, brain and liver cancers as well as head and neck tumors.

IVMT-Rx-4 was developed by InVaMet Therapeutics, a company co-founded by Fisher, and is an intermediate synthesis product related to the earlier compound PDZ1i. According to the researchers, the newer molecule has improved water solubility, lower cellular efflux and enhanced sensitivity compared with unmodified PDZ1i, characteristics that may improve its drug-like behavior. The team is now exploring whether IVMT-Rx-4 can be formulated as an oral medicine. Additional studies will be required to determine its absorption, metabolism, dosing, long-term safety and effectiveness in larger animal models before human trials can be considered.

The work involved investigators from VCU Massey Comprehensive Cancer Center, the VCU Institute of Molecular Medicine, the VCU Center for Drug Discovery and the departments of Medicinal Chemistry and Cellular, Molecular and Genetic Medicine, along with collaborators at Cornell University and Virginia Tech. Senior author Paul B. Fisher said the research identifies a direct drug target and establishes IVMT-Rx-4 as a promising chemical probe for developing new cancer treatments. Jiong Li, the study’s co-corresponding author, emphasized that metastatic head and neck cancer remains extremely difficult to manage and that therapies capable of preventing spread and overcoming resistance are urgently needed.

The findings do not yet demonstrate that IVMT-Rx-4 can cure patients, and no FDA-approved treatment currently eliminates all cancer stem cells. However, the results offer a mechanistic explanation for how a single molecular target might affect tumor growth, metastasis, stem-cell maintenance and chemotherapy resistance at the same time. If future studies confirm the compound’s safety and therapeutic activity, MDA-9/Syntenin inhibition could become a new strategy for treating aggressive HNSCC and potentially other cancers driven by the same metastatic and drug-resistant pathways.

Subject of Research: MDA-9/Syntenin inhibition, cancer stem cells, metastasis and chemotherapy resistance in head and neck squamous cell carcinoma

Article Title: Targeting MDA-9/syntenin-1 (SDCBP) as a strategy to eliminate head and neck squamous cell carcinoma stem cells

News Publication Date: 27 June 2026

Web References: https://www.sciencedirect.com/science/article/pii/S0304383526004568?via%3Dihub; https://www.masseycancercenter.org/news/2026/innovative-targeted-therapy-halts-prostate-cancer-spread-to-the-bone/; https://www.masseycancercenter.org/news/massey-scientists-awarded-r01-to-investigate-treatment-options-for-advanced-prostate-cancer/

References: Cancer Letters, DOI: 10.1016/j.canlet.2026.218692

Image Credits: VCU

Keywords: Head and neck cancer, head and neck squamous cell carcinoma, HNSCC, MDA-9, Syntenin, SDCBP, IVMT-Rx-4, cancer stem cells, chemotherapy resistance, cisplatin, metastasis, targeted cancer therapy, small-molecule inhibitors

Stem cells, remarkable for their ability to give rise to various cell lineages, rely on tightly controlled signaling networks to maintain their stemness—the capacity for indefinite self-renewal without premature differentiation. Among myriad factors, glycogen synthase kinase 3 (GSK3) isoforms have long suggested roles in modulating these processes, but their precise functions, especially concerning isoform-specific actions, have remained elusive. This new research decisively delineates GSK3α as a vital checkpoint, operating distinctly from its close relative GSK3β, in orchestrating stem cell maintenance.

At the core of the study is the demonstration that GSK3α exerts a state-dependent influence on stem cells. Unlike prior notions suggesting a redundant interplay with GSK3β, GSK3α’s role transcends mere backup and emerges as a critical guardian preventing stem cells from veering off the delicate path of pluripotency. The researchers extensively characterized multiple stem cell states, including naïve, primed, and lineage-committed forms, revealing that GSK3α’s activity patterns dynamically adjust to safeguard each state’s integrity.

Molecular analyses highlight that GSK3α directly modulates transcriptional networks closely linked to stemness gene signatures. It influences key pluripotency factors while simultaneously repressing differentiation cues, thus acting as a molecular “gatekeeper.” Advanced genome-wide chromatin immunoprecipitation and RNA sequencing experiments unveiled a suite of target genes and regulatory elements under GSK3α’s control. This level of precision points to a sophisticated mechanism by which GSK3α calibrates gene expression programs essential for stem cell identity.

Intriguingly, the study also demonstrates that pharmacological inhibition or genetic ablation of GSK3α precipitates rapid loss of stemness, promoting premature differentiation. This finding contrasts with the effects of targeting GSK3β and underscores the non-overlapping functions these isoforms fulfill. Such insights could recalibrate therapeutic strategies that aim to manipulate GSK3 activity to control stem cell fate decisions in regenerative treatments and oncology.

In delineating the pathways influenced by GSK3α, the researchers identified a complex interplay with signaling cascades such as the Wnt/β-catenin pathway, Notch, and Hedgehog pathways—each critical for developmental processes. GSK3α fine-tunes these pathways, thereby ensuring that stem cells receive consistent cues to either maintain their undifferentiated state or commit to differentiation with exquisite spatial and temporal precision.

The study extends beyond rodents and cell lines, incorporating human pluripotent stem cell models to affirm translational relevance. These human models illuminated conserved roles for GSK3α, suggesting that this checkpoint mechanism is evolutionarily preserved. The data thus pave the way for explorations into human disease contexts where stem cell dysregulation plays a pathogenic role, including diverse cancers and degenerative diseases.

One of the most compelling aspects of the research is the identification of GSK3α as a potential target for fine-tuning stem cell therapies. Designing selective modulators that harness GSK3α’s regulatory properties could revolutionize approaches to tissue engineering, organ regeneration, and even anti-cancer strategies by exploiting the vulnerable points in stem cell regulatory machinery.

Furthermore, this work challenges the prevailing paradigm that often grouped GSK3α and GSK3β functions indiscriminately. It calls for a refined perspective that considers isoform-specific roles and how discrete molecular activities integrate into broader cellular contexts. This nuanced understanding enhances our ability to precisely manipulate stem cell behavior without off-target effects that have hampered clinical translation.

The researchers employed cutting-edge technologies including CRISPR-Cas9 gene editing, single-cell RNA sequencing, and live cell imaging, enabling them to track dynamic changes in the stem cell population and directly observe GSK3α’s impact in real-time. This multi-modal approach solidified the functional importance of GSK3α and dispelled uncertainties about its mechanistic contribution.

Importantly, by delineating the “stemness checkpoint,” the study proposes a conceptual framework whereby stem cells are viewed as entities regulated by vigilant molecular sentinels like GSK3α. This perspective enhances our grasp of stem cells not merely as passive reservoirs but as active participants finely regulated to balance renewal and differentiation in a context-dependent manner.

The authors also explored the connection between dysregulated GSK3α signaling and disease susceptibility, suggesting that aberrations in this checkpoint may contribute to uncontrolled stem cell proliferation in cancer or inadequate renewal in degenerative conditions. Hence, therapeutic modulation might restore normal homeostasis in diseased tissues or augment the efficacy of stem cell-based interventions.

The implications for developmental biology are profound, as the study clarifies how distinct developmental stages preserve their unique identity by integrating GSK3α’s regulatory signals. This helps decode fundamental puzzles about embryonic development, lineage specification, and cellular plasticity, enriching the toolkit for developmental and regenerative biology research.

Looking forward, this discovery opens new avenues for investigating how other isoform-specific kinases might regulate cellular states in diverse biological contexts. It invites a broader reexamination of protein kinase functions with the specificity that can revolutionize our understanding of cellular regulation and disease mechanisms.

In summary, the revelation that GSK3α functions as a critical stemness checkpoint across multiple stem cell states revolutionizes the current understanding of stem cell biology. It equips scientists and clinicians with novel insights and tools to manipulate stem cell fate with unprecedented precision, heralding a new era in regenerative medicine and targeted cancer therapies.

Subject of Research: The role of GSK3α as a regulatory checkpoint in maintaining stemness across different stem cell states.

Article Title: GSK3α functions as a stemness checkpoint across multiple stem cell states.

Article References:
Wang, D., Wang, X., Malki, S. et al. GSK3α functions as a stemness checkpoint across multiple stem cell states. Cell Res (2026). https://doi.org/10.1038/s41422-026-01245-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41422-026-01245-5

Role of BRPF1 in Gastrointestinal Cancers

Hepatocellular Carcinoma (LIHC)

• Oncogenic Function: BRPF1 acts as an oncogene in liver cancer (LIHC), with increased expression linked to tumor progression.
• Regulation: Overexpression may be driven by transcription factors such as SP1 and mutant p53 variants (e.g., p53R249S, p53Y220C), which bind BRPF1 regulatory elements, promoting chromatin remodeling and histone acetylation.
• Environmental Influence: Exposure to environmental toxins like endosulfan induces BRPF1, while inflammation-related cytokine NFα decreases its expression.
• Prognostic Marker: Elevated BRPF1 correlates with poor overall and disease-free survival, and its expression is positively associated with proliferation markers (Ki67) and other oncogenic factors (MOZ, MORF, MTA2).
• Cancer Stemness: BRPF1 is upregulated in liver cancer stem cells (CD133+), maintaining stemness via regulation of NOTCH1, OCT4, and EPCAM.
• Mechanism: Regulates oncogenes E2F2 and EZH2 by modulating MOZ/MORF acetyltransferase activity and H3K14 acetylation.
• Therapeutic Targeting: Genetic knockout or pharmacological inhibition (e.g., GSK5959, OF-1, NI-57) reduces tumor growth, inducing senescence and cell cycle arrest.

Colon Adenocarcinoma (COAD)

• BRPF1 upregulation driven by Pygo2, a Wnt/β-catenin coactivator.
• BRPF1 promotes proliferation and stem-like properties.
• Targeting BRPF1 reduces colony formation and tumor growth in Pygo2-high cells.

Gastrointestinal Stromal Tumor (GIST)

• BRPF1 identified as essential in genome-wide CRISPR-Cas9 screens.
• Pharmacological inhibition results were inconsistent regarding cell proliferation, possibly due to low drug doses.

Esophageal Cancer (ESCA)

• BRPF1 promoter shows an active chromatin state in cfDNA from ESCA patients, suggesting a potential diagnostic/prognostic marker function.

Role of BRPF1 in Genitourinary Tumors

Prostate Cancer (PCa)

• Expression inversely reported but increased BRPF1 associates with progression parameters (Gleason score, stage, recurrence risk).
• BRPF1 stabilizes through USP35-mediated deubiquitination, enhancing transcription of SREBP2, which drives mevalonate metabolism.
• Contributes to taxane resistance by regulating ABCB1-mediated drug efflux and cell cycle progression.
• BRPF1 inhibition reverses resistance and synergizes with chemotherapy.

Ovarian Cancer (OC)

• Genomic amplifications and aberrant cytoplasmic localization via fucosylation noted; mRNA-protein expression discrepancies exist.
• High BRPF1 correlates with poor outcomes and advanced disease.
• Promotes proliferation, anaerobic metabolism, and Wnt signaling.
• Knockdown induces apoptosis, cell cycle disruption, and DNA damage.
• Involved in immune modulation, affecting immune checkpoint expression and immune infiltration.
• Pharmacological inhibition impacts lipid metabolism and inflammatory pathways.
• BRPF1 is part of key gene signatures predicting prognosis.

Role of BRPF1 in Brain Cancers

• Elevated in high-grade gliomas, where inhibition reduces proliferation.
• Involved in adult Sonic hedgehog medulloblastoma with mutations contributing to tumorigenesis, potentially independent of SMO mutations.
• BRPF1 mutations promote neuronal dedifferentiation and tumor formation.

Role of BRPF1 in Skin Cancers

• Overexpressed in melanoma at both mRNA and protein levels.
• Combined pharmacological inhibition with CDC7 inhibitor impacts tumor cell survival pathways (MYC, IGF1R) and induces apoptosis and cell cycle arrest.

Summary of Mechanisms & Therapeutic Implications

• Chromatin Remodeling and Histone Acetylation: BRPF1 modulates acetyltransferase activity (MOZ/MORF complexes) influencing transcription of oncogenes and pathways crucial for cell cycle progression and stemness.
• Cancer Stem Cell Maintenance: BRPF1 sustains stem-like cell populations, which are critical for tumor propagation and resistance.
• Metabolism and Drug Resistance: Especially in prostate cancer, BRPF1 influences metabolic pathways and chemoresistance mechanisms.
• Therapeutic Target: Pharmacological inhibitors of BRPF1 (e.g., GSK5959, OF-1, NI-57) show promise by arresting the cell cycle, inducing apoptosis, and reducing tumor growth both in vitro and in vivo.
• Diagnostic and Prognostic Biomarker: BRPF1 expression correlates with progression, stage, and survival in multiple cancers, making it a candidate biomarker.

In conclusion, BRPF1 is a multifaceted epigenetic regulator with oncogenic roles in gastrointestinal, genitourinary, brain, and skin cancers. It influences key pathways related to chromatin remodeling, metabolism, stemness, and drug resistance, positioning it as a valuable diagnostic marker and therapeutic target.

Ubiquitination is a post-translational modification that marks proteins for degradation, a process critical for cellular homeostasis. The review highlights the importance of the ubiquitin-proteasome system (UPS) in CSCs, elucidating how dysregulation in this system has been linked to tumorigenesis. Understanding these connections sheds light on potential targets for innovative cancer therapies. The intricate interplay between ubiquitination and cancer stem cell biology may reveal vulnerabilities that could be exploited in the fight against malignancies.

The role of E3 ubiquitin ligases, the enzymes responsible for tagging proteins with ubiquitin for degradation, is also discussed. These ligases selectively target proteins that are pivotal in CSC survival and function. By modulating the activity of these ligases, researchers hope to influence the stability of CSC-associated proteins, thereby impacting the self-renewal and differentiation capabilities of CSCs. This novel perspective suggests that through careful manipulation of the ubiquitination landscape, scientists can develop effective strategies to combat cancer.

Deubiquitinases, which counteract the function of ubiquitin ligases, are equally significant in the context of CSCs. The review outlines how these enzymes not only prevent the degradation of crucial proteins but also actively participate in the signaling cascades that dictate stem-like properties in cancer cells. This dual role introduces a complex regulatory dance that determines the fate of CSCs. Disrupting this balance could lead to a loss of stemness, making CSCs more susceptible to conventional therapies.

The review presents a thorough examination of various signaling pathways influenced by ubiquitination. Key pathways such as Notch, Wnt/β-catenin, and Hedgehog are identified as essential mediators of CSC properties. By understanding how ubiquitination interacts with these pathways, researchers can identify potential therapeutic targets that can disrupt the malignant behavior of CSCs. Such insights consolidate the idea that targeting the UPS could be a viable strategy for eradicating tumors that have resisted traditional treatments.

As scientific inquiries into the regulation of CSCs expand, the implications for cancer therapies become increasingly apparent. The potential for developing E3 ligase-targeting drugs is highlighted as an innovative avenue, with existing proteasome inhibitors like bortezomib already demonstrating efficacy in certain cancer types. This lays the groundwork for a new class of targeted treatments that can be combined with existing chemotherapy or immunotherapy protocols.

The significance of combinatorial therapies is a key focal point in this discussion. By integrating Ub-targeted therapies with established treatment modalities, there is substantial promise for enhancing patient outcomes. The synergistic effects of such combinations could lead to more robust responses in treatment-resistant cancers, which often harbor CSCs responsible for relapse.

Furthermore, the review emphasizes the necessity for ongoing investigation into both E3 ligases and deubiquitinases. Since the landscape of ubiquitination is vast and complex, precise characterization of these enzymes could yield significant breakthroughs in oncology. With a better grasp of how ubiquitin system modulations can affect CSC behavior, researchers can tailor medications that are both effective and highly targeted, minimizing the collateral damage associated with conventional cancer therapies.

Importantly, this article does not merely present findings; it also discusses broader implications for the field of cancer research. The integration of molecular-level insights with clinical applications demonstrates a progressive shift towards more personalized medicine approaches. As researchers continue to identify the regulatory factors governing CSCs through ubiquitination, there is hope for refining strategies against cancer recurrence and treatment resistance.

As we reflect on the increasing sophistication of molecular oncology, the insights provided by the review in "Genes & Diseases" represent a promising shift in our approach to tackling one of the most challenging aspects of cancer treatment. The potential to not only prolong life but improve its quality through focused therapies stemming from a deep understanding of CSCs is an exciting frontier in medical science.

With each step forward in research, the dream of achieving better, more effective therapies becomes a tangible reality. The pathways outlined in the recent review signal a call to action for researchers and clinicians alike—a reminder that a collaborative and holistic approach is essential in the relentless quest to outsmart cancer.

In conclusion, the exploration of ubiquitination’s role in CSC functionality encapsulates a critical dimension of contemporary cancer research. Continued advancement in this area not only enlightens our understanding of cancer dynamics but also equips us with the necessary tools to confront the multifaceted nature of malignancies in the future.

Subject of Research: The role of ubiquitination in cancer stem cell regulation.

Article Title: Key Roles of Ubiquitination in Regulating Critical Regulators of Cancer Stem Cell Functionality.

News Publication Date: October 2023.

Web References: Genes & Diseases Journal

References: Qianqian Guo, Hai Qin, Zelong Chen, Wenzhou Zhang, Lufeng Zheng, Tingting Qin, Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality, Genes & Diseases, Volume 12, Issue 3, 2025, 101311.

Image Credits: Genes & Diseases.

Keywords: Cancer stem cells, ubiquitination, E3 ubiquitin ligases, deubiquitinases, therapeutic targets, tumor progression, drug resistance.